Microdosing: the idea, the research and the reality

Everyone seems to know someone who microdoses: the founder with the morning routine, the forum thread about sharper focus, the friend of a friend who "just feels more like themselves". It's a good story, and it raises a fair question: what happens when researchers run the same practice with a placebo group alongside? Let's go through what people mean by microdosing, what the controlled studies measured, and what nobody knows yet.

Microdosing: what people hope for, and what trials have measured

• Microdosing usually means taking a small amount of a psychedelic, below the level that produces a full psychedelic experience, repeatedly over weeks. There's no single agreed definition of the amount or schedule.
• In placebo-controlled trials of psilocybin microdosing, the main measured results have mostly been small or null for mood, cognition and well-being. One pooled analysis found a narrow effect on a creativity score that held up after adjusting for dose guesses. People often guess correctly which capsule they got, which makes the comparison harder to read.
• Self-reports and observational studies look more positive, but they can't separate a drug effect from expectation, a new routine, or the fact that people who choose to microdose are not a random sample.
• Long-term safety is unknown. There are theoretical concerns, raised in a 2024 review, about repeated stimulation of one serotonin receptor type (5-HT2B) that has been linked to heart-valve problems with other drugs. That's a hypothesis; no one has shown it happens with microdosing.
• The law follows the product, not the intention. In the Netherlands, as of 8 October 2026, fresh truffles and mushrooms are treated differently, and sources disagree about dried truffles.
• Clinical trials of psilocybin for depression used full doses with therapist support. They're a different intervention from microdosing.

What people mean by microdosing

The word borrows from pharmacology, but there's no official microdose of psilocybin. Researchers and users describe it as a "sub-hallucinogenic" or "sub-perceptual" amount taken repeatedly. NCCIH, the US National Center for Complementary and Integrative Health, describes people taking very small amounts (it gives one-tenth or one-twentieth of a typical nonclinical dose as examples) in the hope of improving mental health, productivity or pain, and states that "it is not clear if microdosing is safe or effective" (NCCIH).

Named routines and branded packs exist, but this page follows the question beneath them: what has research found when microdosing is compared with placebo?

Why this is hard to test

Imagine a month-long study. You expect to feel better. You've read the forums. You're paying attention to your mood every day. Now add the fact that many people can tell when they've taken something active, even at a low amount. That is the knot researchers have been trying to untie.

Two ideas help:

• Expectancy. If you expect a benefit, you may notice or report one, whatever you took. The placebo response in depression and well-being studies can be large.
• Blinding. A trial only works as a blind if participants can't tell which condition they're in. If a person works out they've got the active dose, the placebo comparison weakens, because their expectation changes too. Several microdosing studies report exactly this problem.

So the useful question is not "do people report benefits?" (they do) but "do people who got the real thing do better than people who got a lookalike, even when they can't tell the difference?"

What controlled studies found

Here are the main placebo-controlled studies of psilocybin or psilocybin-containing material, with who was studied and what was used. Doses are reported as the studies describe them, not as advice.

• Study: Szigeti et al., 2021, *eLife*; Who and what: 191 completed the study; the full sample described used mostly LSD or LSD analogues (61% plus 14%), with psilocybin mushrooms used by 57 people (24%). People chose their own substance and dose; purity was not verified; Design: "Self-blinding" citizen science: participants followed online instructions to add their own placebo control over 4 weeks; What was found: Both groups improved on all psychological outcomes, with no significant difference between microdose and placebo groups. Small acute differences were explained by people breaking the blind
• Study: Marschall et al., 2022, *J Psychopharmacol*; Who and what: Adults; 52 were included in the repeated-measures analyses for the first lab sessions. Dose: 0.7 g of dried psilocybin truffle (analysed at about 1.5 mg of alkaloids); Design: Preregistered, double-blind, placebo-controlled crossover; sub-hallucinogenic dose every third day over 3 weeks; What was found: No effect on emotion processing or on anxiety and depression compared with placebo. Participants broke blind in the second block
• Study: Cavanna et al., 2022, *Transl Psychiatry*; Who and what: 34 people who were starting to microdose; 0.5 g of dried *Psilocybe cubensis* mushrooms; Design: Double-blind, placebo-controlled; subjective, behavioural, creativity, perception, cognition and EEG measures; What was found: Acute effects were stronger on the active dose, but only for those who correctly identified it. EEG theta power was lower. No evidence of better well-being, creativity or cognition; a few small changes towards cognitive impairment. Authors conclude expectation underlies at least some anecdotal benefits
• Study: Prochazkova, Marschall et al., 2026, *Neuropharmacology* (two trials); Who and what: Psilocybin truffles, semi-naturalistic settings; Design: Two randomised, double-blind, placebo-controlled longitudinal trials; What was found: No significant behavioural or subjective differences from placebo. Some early effects on social cognition, mood and cognitive flexibility did not survive correction for multiple comparisons. Participants "remained effectively blinded"; negative bodily feelings were stronger in the active condition
• Study: Prochazkova et al., 2026, *Neuropharmacology* (creativity mega-analysis); Who and what: Three double-blind placebo-controlled trials pooled, N = 171; Design: Mega-analysis; What was found: Active microdosing increased the ratio of original responses on a divergent-thinking task, but only when dose relative to body weight was considered. The effects survived controlling for dose guess and demographic biases. No effects on other divergent-thinking scores or on convergent thinking
• Study: Petranker et al., 2026 (preprint, not peer reviewed); Who and what: 39 adults with mild-to-moderate major depression; 2 mg psilocybin versus placebo, weekly for four weeks, then open-label; Design: Phase II randomised, double-blind, placebo-controlled; What was found: Similar reductions on the main depression score in both groups after four weeks (psilocybin −5.4; placebo −6.0). Authors report it was safe and well tolerated, with no serious treatment-emergent adverse events, and that trial participation itself coincided with improvement

Sources for the table: Szigeti 2021, Marschall 2022, Cavanna 2022, Prochazkova 2026, two trials, Prochazkova 2026, creativity, Petranker 2026 preprint. The Petranker study's protocol is published in BJPsych Open.

A few readings worth keeping in mind:

• The pattern is consistent, not total. The creativity mega-analysis found a narrow effect (originality of ideas) alongside no effect on other scores, and only when dose was adjusted for body weight, though it did survive controlling for whether people guessed their capsule. One narrow result on one test doesn't add up to "microdosing makes you creative".
• Outcomes depend on the question. Studies that measured depression and anxiety in healthy adults, or mood and cognition, tend to find little against placebo. Most were in healthy volunteers rather than people with clinical conditions, so they don't cover everything people hope for.
• Short studies, few doses. Trials run for weeks. They can't show what months or years of use do.

The 2024 to 2026 reviews

Reviews help when single trials are small:

• A 2026 systematic review and meta-analysis pooled 24 studies (3,681 participants) of psychedelic microdosing in healthy adults, mostly LSD and psilocybin. Randomised trials showed subjective and physiological effects "but minimal impact on cognition, creativity, or sustained mood"; observational studies showed mood and personality improvements, "likely influenced by expectancy or lifestyle factors". Pooled randomised trials found no clear immediate reduction in depressive symptoms (SMD −0.19, 95% CI −0.56 to 0.19) (CNS Drugs, 2026). The meta-analysis included only two parallel randomised trials (n = 117), so it's not a big pool.
• A 2026 systematic review of psilocybin mushroom and truffle microdosing found eleven studies (five quantitative, six qualitative; 3,262 adults), mostly self-reported outcomes, and concluded that "the certainty of the evidence is low, and a causal effect of microdosing cannot be inferred". About 86% of motivations were non-medical (Page et al., 2026, Frontiers in Psychiatry).
• A 2024 rapid review by Polito and Liknaitzky counted 19 placebo-controlled studies and argued the "it's all placebo" conclusion is premature: few studies, small samples, few doses, possibly too-low doses, mostly non-clinical populations (J Psychopharmacol, 2024). That is the fair counterpoint: the research hasn't shown a reliable benefit so far, and it hasn't ruled one out under other conditions either.

So what do the best controlled psilocybin studies show so far? Mostly nothing beyond placebo, though reviewers disagree on how conclusive that is.

Why self-reports look different

Observational studies ask people who already microdose how they feel. A well-known early example is a 2018 Dutch study at a microdosing event where participants completed creativity tasks before and after taking a non-blinded microdose; performance on convergent and divergent thinking tasks improved, and the authors themselves called for placebo-controlled designs (Prochazkova et al., 2018, Psychopharmacology). Later placebo-controlled work from the same Leiden group, summarised above, found much less.

Why can self-reports run ahead of trials?

• Everyone in a self-report study knows what they took.
• Self-selection. People who choose to microdose, and keep going, may differ from those who never start.
• Microdosers often change other things at the same time: sleep, exercise, structure, attention to their mood.
• Interest is high. A nationally representative US survey (fielded December 2023 to January 2024) estimated that 12.1% of adults had used psilocybin in their lifetime, and that, among past-year users, 46.9% microdosed the last time (Priest et al., 2026, Addiction). Popular is a different question from effective.

Gamers, founders and focus: who talks about microdosing

You may have noticed that the people talking about microdosing are often the same people who talk about focus, productivity, gaming or startups. That tells us who is interested, not what the practice does. When you hope for an edge, expectation can colour what you notice and report, which is one more reason placebo-controlled results matter. None of the placebo-controlled studies above measured gaming performance, work output or longevity.

Safety: what's known, and what isn't yet

What studies report. A 2025 systematic review of microdosing LSD and psilocybin (31 studies) found side effects were "typically dose-dependent, mild, and short-lived", with increased blood pressure, anxiety and cognitive impairment among the common ones, while noting that reporting was inconsistent and many studies were short (Modzelewski et al., 2025, Neuropharmacology). NCCIH lists, among reported effects of microdosing, insomnia, increased anxiety, low mood, physical discomfort and poor focus. A "micro" label does not mean a guaranteed lack of effect.

What's theoretical. Separately, some drugs taken regularly over long periods have been linked to heart-valve problems through the 5-HT2B receptor (methysergide, pergolide and fenfluramine are the examples named). A 2024 review by Rouaud et al. made that argument: it says psilocybin and LSD share structural similarities with those drugs, discusses the link between drug-induced cardiac fibrosis and the 5-HT2B receptor, and states that the long-term effects of microdosing on cardiac health "remain unknown"; it recommends evaluating safety in future studies (Rouaud et al., 2024, J Psychopharmacol). This is a theoretical concern based on receptor pharmacology and comparison with other drugs: valve disease hasn't been reported from microdosing psilocybin in the sources linked here, and no long-term study has looked for it.

Who should especially be careful. For psilocybin generally, NCCIH says it is not safe for people with psychotic conditions such as schizophrenia, or severe forms of bipolar disorder, and lists increased blood pressure and heart rate among adverse effects. An analysis of online reports found that 47% of 62 reports of classic psychedelics taken with lithium involved seizures; the authors considered the finding provisional (Nayak et al., 2021, Pharmacopsychiatry). Information on interactions with antidepressants and other serotonergic medicines is limited, and that's a reason to ask a pharmacist or doctor, not a reason to assume it's fine. Our supplement and drug interactions guide explains how to check a medicine. Don't stop a prescribed medicine to try a protocol.

If you feel severely unwell, get urgent medical help (112 in the EU) and say what you took.

Microdosing and the depression trials: two different things

The two often get mixed up. Positive trials for depression, such as the phase 2 study in which 25 mg of a synthetic psilocybin beat a 1 mg control at three weeks (Goodwin et al., 2022, NEJM), used a single full dose with psychological support, in screened patients. Microdosing is a different regimen: much smaller amounts, repeated, without support, so a result for one doesn't transfer to the other. The Petranker trial above tested a repeated 2 mg dose in people with depression, and it didn't beat placebo on its main measure, though it's one small study and the preprint hasn't been through peer review.

The Netherlands: why the form of the product matters

"Microdosing is legal in the Netherlands" is a common shorthand, but the law doesn't regulate an intention or a quantity; it regulates substances and products. As of 8 October 2026, according to Dutch addiction-care sources and the Opium Act text (consulted that day):

• Fresh truffles (sclerotia) are not covered by the Opium Act and are sold in smartshops under the Commodities Act (Warenwet) (Jellinek).
• Dried truffles are disputed. Jellinek says they fall under List I of the Opium Act (Jellinek), while DRUGSinfo and Drugs en Uitgaan say truffles aren't covered and make no distinction for dried ones. The statute text names psilocine and psilocybine (List I) and mushrooms (List II), not truffles. If you're weighing a dried product, treat it as the riskier reading.
• Magic mushrooms (paddo's), fresh or dried, are on List II and have been prohibited for sale since 2008 (DRUGSinfo).

So a pack, capsule or powder marketed for microdosing needs checking for what it actually is, and in what form, before anyone assumes the truffle position covers it. A pack being on sale says nothing about whether it works. Other countries differ, usually more strictly. A Dutch ban on certain designer-drug groups took effect on 1 July 2025; the government page doesn't mention truffles, and nothing we found changes the truffle position. Laws change, so check current rules.

The doses in the table are what each study used, in its own population and setting; this page gives no amounts or schedules of its own.

What would sharpen the picture

• Larger, longer randomised trials in people with clinical depression or anxiety, not just healthy volunteers (the published protocol for the Petranker trial describes a long-term extension with follow-up for up to two years).
• Better blinding, for example active placebos, and reporting of whether participants guessed correctly.
• Standardised preparations. Truffles and mushrooms vary in alkaloid content (one analysis found psilocybin ranging from 59.3 to 167.8 µg per 100 mg of fresh sclerotia in the samples tested), which makes comparing studies hard (Pellegrini et al., 2013).
• Long-term safety monitoring, including long-term cardiac monitoring, which Rouaud et al. recommend evaluating.

What the research can tell you today

Microdosing is an interesting idea with vivid stories behind it and, so far, modest controlled evidence. If your question is "should I expect a measurable boost?", placebo-controlled psilocybin studies mostly say "not reliably", while the researchers who disagree say the right tests haven't been done yet. If medicines or a mental-health condition are involved, talk to a clinician first. We'll update this guide when new controlled trials report.

Where to read next

Microdosing sits inside a bigger conversation. These guides fill in the rest.

• Microdosing products and protocols explained, for what truffle microdosing packs contain, where the Fadiman and Stamets schedules came from and what controlled trials have tested.
• Magic mushrooms and truffles, for how the two differ as products, including their separate legal positions in the Netherlands.
• Truffle safety, difficult experiences and getting support, for who should avoid psilocybin, what difficult experiences look like and the Dutch help options.
• What to expect from magic truffles, for the timing, why the same pack differs between people, difficult moments and who should skip them.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.